BioMarin Pharmaceutical Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 BioMarin Pharmaceutical Inc 公司

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

BioMarin Pharmaceutical Inc簡介



公司代碼BMRN

公司名稱BioMarin Pharmaceutical Inc

上市日期Jul 23, 1999

CEOHardy (Alexander)

員工數量3040

證券類型Ordinary Share

年結日Jul 23

公司地址770 Lindaro Street

城市SAN RAFAEL

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94901

電話14155066700

網址https://www.biomarin.com/

公司代碼BMRN

上市日期Jul 23, 1999

CEOHardy (Alexander)

BioMarin Pharmaceutical Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+6650.00%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

46.80K

-16570.00%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-3304.00%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+6650.00%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-2428.00%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+6650.00%

Ms. Barbara W. Bodem

Independent Director

8.83K

+6650.00%

Dr. Athena M. Countouriotis, M.D.

Independent Director

8.83K

+6650.00%

Mr. G. Eric Davis

Executive Vice President, Secretary, Chief Legal Officer

--

Mr. Brian R. Mueller, CPA

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+6650.00%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

46.80K

-16570.00%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-3304.00%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+6650.00%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-2428.00%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+6650.00%

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Voxzogo

218.39M

28.70%

Vimizim

182.75M

24.02%

Naglazyme

122.03M

16.04%

Palynziq

108.78M

14.30%

Aldurazyme

53.71M

7.06%

其他

75.16M

9.88%

地區USD

名稱

營收

佔比

United States

274.11M

36.03%

Europe

195.18M

25.65%

Rest of the world

140.19M

18.43%

Latin America

97.62M

12.83%

ALDURAZYME net product revenues marked by Sanofi

53.71M

7.06%

業務

地區

業務USD

名稱

營收

佔比

Voxzogo

218.39M

28.70%

Vimizim

182.75M

24.02%

Naglazyme

122.03M

16.04%

Palynziq

108.78M

14.30%

Aldurazyme

53.71M

7.06%

其他

75.16M

9.88%

股東統計

更新時間: 2月6日週五

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

9.41%

BlackRock Institutional Trust Company, N.A.

8.98%

PRIMECAP Management Company

7.93%

Dodge & Cox

7.64%

State Street Investment Management (US)

4.56%

其他

61.48%

持股股東

佔比

The Vanguard Group, Inc.

9.41%

BlackRock Institutional Trust Company, N.A.

8.98%

PRIMECAP Management Company

7.93%

Dodge & Cox

7.64%

State Street Investment Management (US)

4.56%

其他

61.48%

股東類型

持股股東

佔比

Investment Advisor

46.66%

Investment Advisor/Hedge Fund

37.37%

Hedge Fund

6.70%

Pension Fund

3.03%

Research Firm

1.59%

Sovereign Wealth Fund

1.40%

Individual Investor

0.74%

Bank and Trust

0.67%

Venture Capital

0.35%

其他

1.49%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

1342

187.67M

97.68%

-21.49M

2025Q3

1334

187.86M

111.13%

-2.15M

2025Q2

1344

190.17M

114.04%

-8.63M

2025Q1

1331

198.83M

113.78%

-19.35M

2024Q4

1317

196.49M

110.91%

+4.70M

2024Q3

1283

191.71M

111.61%

-4.43M

2024Q2

1271

195.66M

108.22%

+2.33M

2024Q1

1257

193.46M

109.63%

-14.58M

2023Q4

1275

195.75M

103.93%

+7.49M

2023Q3

1255

188.56M

102.57%

+2.75M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

18.49M

9.63%

-419.17K

-2.22%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

17.25M

8.98%

-790.94K

-4.38%

Sep 30, 2025

PRIMECAP Management Company

15.23M

7.93%

-542.89K

-3.44%

Sep 30, 2025

Dodge & Cox

14.69M

7.64%

-421.51K

-2.79%

Sep 30, 2025

State Street Investment Management (US)

8.76M

4.56%

-83.15K

-0.94%

Sep 30, 2025

Viking Global Investors LP

8.32M

4.33%

-3.97M

-32.28%

Sep 30, 2025

AQR Capital Management, LLC

5.93M

3.09%

+351.54K

+6.30%

Sep 30, 2025

Geode Capital Management, L.L.C.

3.54M

1.84%

+67.68K

+1.95%

Sep 30, 2025

Rothschild & Co Asset Management Europe SCS

2.63M

1.37%

+317.58K

+13.74%

Nov 30, 2025

Millennium Management LLC

2.63M

1.37%

-207.15K

-7.31%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

First Trust NYSE Arca Biotechnology Index Fund

3.44%

Global X Genomics & Biotechnology ETF

2.98%

Invesco Biotechnology & Genome ETF

2.47%

First Trust Health Care Alphadex Fund

2.15%

Goldman Sachs Future Health Care Equity ETF

2.15%

State Street SPDR S&P Biotech ETF

1.93%

WealthTrust DBS Long Term Growth ETF

1.86%

Alger Russell Innovation ETF

1.84%

Virtus LifeSci Biotech Products ETF

1.5%

VanEck Biotech ETF

1.4%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.44%

Global X Genomics & Biotechnology ETF

佔比2.98%

Invesco Biotechnology & Genome ETF

佔比2.47%

First Trust Health Care Alphadex Fund

佔比2.15%

Goldman Sachs Future Health Care Equity ETF

佔比2.15%

State Street SPDR S&P Biotech ETF

佔比1.93%

WealthTrust DBS Long Term Growth ETF

佔比1.86%

Alger Russell Innovation ETF

佔比1.84%

Virtus LifeSci Biotech Products ETF

佔比1.5%

VanEck Biotech ETF

佔比1.4%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據